Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...

The phase 3 DREAM3R study randomized patients 2:1 to receive durvalumab 1500 mg every 3 weeks plus chemotherapy every 3 weeks for 4 to 6 cycles, followed by durvalumab maintenance 1500 mg every 4 ...

NORTH PHILADELPHIA (WPVI) -- Mesothelioma is one of the hardest cancers to treat, but from surgical techniques to drug combinations, progress is slowly being made, giving patients more time and ...

Trends in malignant pleural mesothelioma prevalence in the United States from 2000 to 2020. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...